RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023 06:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the...
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
July 28, 2023 13:24 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring...
Global Color Blind Glasses Markets, 2023-2030: Innovative 3D Printing Technology and Government Initiatives Propel Adoption
July 26, 2023 04:43 ET
|
Research and Markets
Dublin, July 26, 2023 (GLOBE NEWSWIRE) -- The "Global Color Blind Glasses Markets, 2023-2030" report has been added to ResearchAndMarkets.com's offering. Global Color Blind Glasses Market to...
Diabetic Retinopathy Global Market to 2030: Increasing Prevalence of Blindness due to Diabetes Drives Growth
June 29, 2023 07:03 ET
|
Research and Markets
Dublin, June 29, 2023 (GLOBE NEWSWIRE) -- The "Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Intraocular...
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
June 26, 2023 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board...
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
June 12, 2023 02:00 ET
|
Beacon Therapeutics
PRESS RELEASE Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness New leading gene therapy company...
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
June 07, 2023 05:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Mr. Watson’s...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 05, 2023 06:00 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...
Fundus Camera Global Market Report 2023: Increasing Number of Product Launches by Key Players is Expected to Propel Growth
March 01, 2023 09:48 ET
|
Research and Markets
Dublin, March 01, 2023 (GLOBE NEWSWIRE) -- The "Fundus Camera Market, by Product Type, by Modality, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report...
Age-Related Macular Degeneration (AMD) Global Market Report 2022: Featuring F. Hoffman - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharmaceuticals, Bausch Health & Alimera Sciences
January 24, 2023 04:48 ET
|
Research and Markets
Dublin, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis"...